Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for the stock in the near term [10]. Core Insights - The company has demonstrated steady revenue growth, with total revenue of 11.762 billion yuan in H1 2024, reflecting a year-on-year increase of 9.86%. The net profit attributable to shareholders reached 798 million yuan, up 13.13% year-on-year [10]. - The company is focusing on regional expansion, having opened 1,575 new stores during the reporting period, including 842 self-built stores and 293 acquired stores. The total number of chain pharmacies reached 14,736, a year-on-year increase of 27.25% [10]. - The retail business is developing steadily, with retail revenue of 10.398 billion yuan in H1 2024, a year-on-year increase of 8.32%. The gross margin for retail was 40.94% [10]. - The company is actively building a new retail system in the pharmaceutical sector, with a total membership of 96.16 million, a year-on-year growth of 23.84%. Membership sales accounted for 77% of total sales [10]. - The company is expected to see net profits of 1.740 billion yuan, 2.128 billion yuan, and 2.584 billion yuan for the years 2024, 2025, and 2026, respectively, with corresponding EPS of 1.43 yuan, 1.76 yuan, and 2.13 yuan [10]. Summary by Sections Financial Performance - In H1 2024, the company achieved total revenue of 11.762 billion yuan, a 9.86% increase year-on-year, and a net profit of 798 million yuan, up 13.13% [10]. - The gross margin for H1 2024 was 40.05%, with a net profit margin of 7.31% [10]. Store Expansion - The company opened 1,575 new stores in the reporting period, including 842 self-built and 293 acquired stores, resulting in a total of 14,736 chain pharmacies nationwide, a 27.25% increase year-on-year [10]. Business Segments - Retail revenue reached 10.398 billion yuan, growing 8.32% year-on-year, while wholesale revenue was 999 million yuan, increasing by 20.91% [10]. - The company’s high-margin traditional Chinese medicine segment saw significant growth, with revenue of 1.165 billion yuan, a 14.82% increase year-on-year [10]. Membership and New Retail Initiatives - The company has built a membership base of 96.16 million, a 23.84% increase year-on-year, with membership sales contributing 77% to total sales [10]. - Internet sales revenue reached 1.096 billion yuan, a 20.18% increase year-on-year, with O2O sales growing by 26.33% [10].

Investment Rating - The report maintains a "Buy-A" investment rating for the company, with a 6-month target price of 25.40 CNY per share [5][6]. Core Insights - The company achieved a revenue of 11.762 billion CNY in H1 2024, representing a year-on-year growth of 9.86%. The net profit attributable to shareholders after deducting non-recurring items was 786 million CNY, up 15.77% year-on-year [2][5]. - The growth in profits is attributed to both organic and external growth from store expansion, as well as improved management efficiency [2][3]. - The company continues to focus on a "regional focus and steady expansion" strategy, with a total of 14,736 stores as of H1 2024, marking a 27.25% increase compared to H1 2023 [3]. - The overall gross margin for H1 2024 was 40.05%, slightly up by 0.06 percentage points from the previous year, indicating stable profitability [4]. Summary by Sections Revenue and Profit Growth - In H1 2024, the company reported revenues of 117.62 billion CNY, with retail and wholesale segments contributing 103.98 billion CNY (+8.32%) and 9.97 billion CNY (+20.91%) respectively [2][5]. - The net profit attributable to shareholders after non-recurring items was 786 million CNY, reflecting a 15.77% increase year-on-year [2][5]. Store Expansion Strategy - The company has been actively expanding its store network, with 842 new self-built stores, 293 acquired stores, and 440 new franchise stores added in H1 2024 [3]. - The total number of stores reached 14,736, including 3,426 franchise stores, demonstrating a robust growth strategy [3]. Profitability and Management Efficiency - The company's gross margin stood at 40.05% in H1 2024, with specific margins for various product categories: 34.85% for Western and Chinese medicines, 48.74% for traditional Chinese medicine, and 51.10% for non-pharmaceutical products [4]. - Management efficiency improved, as evidenced by a decrease in sales and management expense ratios by 0.15 and 0.20 percentage points respectively [4].

Investment Rating - The investment rating for the company is "Buy" (maintained) [3] Core Views - The company has achieved steady revenue and profit growth in H1 2024, with a revenue of 11.762 billion yuan (up 9.86% year-on-year) and a net profit attributable to shareholders of 798 million yuan (up 13.13% year-on-year) [5] - The company is focusing on regional expansion and steady growth, with a total of 14,736 stores as of H1 2024, including 3,426 franchise stores [7] - The company has adjusted its profit forecasts for 2024-2026, expecting net profits of 1.607 billion yuan, 1.906 billion yuan, and 2.297 billion yuan respectively [5] Financial Performance Summary - H1 2024 revenue: 117.62 billion yuan (up 9.86% year-on-year); Q2 2024 revenue: 57.91 billion yuan (up 6.45% year-on-year) [5] - H1 2024 gross margin: 40.05% (up 0.06 percentage points); net margin: 7.31% (down 0.15 percentage points) [5] - Retail business revenue: 103.98 billion yuan (up 8.32%); wholesale business revenue: 9.97 billion yuan (up 20.91%) [6] Business Expansion and Strategy - The company added 1,575 new stores in H1 2024, including 842 self-built stores and 440 franchise stores [7] - The company emphasizes refined, standardized, and systematic operational management, supported by a digital and intelligent management platform [7]

医药生物/医药商业 公 司 研 究 益丰药房（603939.SH） 2024 年 09 月 03 日 2024H1 营收利润稳健增长，门店扩张稳步推进 ——公司信息更新报告 投资评级：买入（维持） 日期 2024/9/2 余汝意（分析师） yuruyi@kysec.cn 证书编号：S0790523070002 开 源 证 券 证 券 研 究 报 告 公司信息更新报告 | --- | --- | |-------------------------|-------------| | | | | 当前股价 ( 元 ) | 18.44 | | 一年最高最低 ( 元 ) | 46.88/17.91 | | 总市值 ( 亿元 ) | 223.58 | | 流通市值 ( 亿元 ) | 223.08 | | 总股本 ( 亿股 ) | 12.12 | | 流通股本 ( 亿股 ) | 12.10 | | 近 3 个月换手率 (%) | 72.05 | 股价走势图 益丰药房 沪深300 -40% -20% 0% 20% 40% 60% 2023-09 2024-01 2024-05 数据来源：聚源 相关研究报告 《营收稳健增长， ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 11.762 billion yuan in H1 2024, representing a year-on-year increase of 9.86%, and a net profit attributable to shareholders of 798 million yuan, up 13.13% year-on-year [3] - The company continues to deepen its regional market presence through a strategy of "new openings + acquisitions + franchising," resulting in a total of 14,736 stores by H1 2024, with 1,575 new stores added since the beginning of the year [3] - The O2O business has shown remarkable growth, with online revenue reaching 1.096 billion yuan in H1 2024, a 20.18% increase, and O2O revenue specifically growing by 26.33% to 878 million yuan [3] Financial Performance Summary - Total revenue (in million yuan) for the years 2022A to 2026E is projected to grow from 19,886 to 33,042, with a CAGR of approximately 14.46% [2] - Net profit attributable to shareholders (in million yuan) is expected to rise from 1,262 in 2022A to 2,319 in 2026E, reflecting a growth rate of 19.59% [2] - The latest diluted EPS is projected to increase from 1.04 in 2022A to 1.91 in 2026E, indicating a strong upward trend in earnings per share [2] Business Segment Overview - Retail business revenue in H1 2024 was 10.398 billion yuan, up 8.32%, while wholesale business revenue reached 999 million yuan, a significant increase of 20.85% [3] - The gross margin for retail business was 40.94%, showing a slight increase, while the wholesale business gross margin was 9.57%, reflecting a decrease of 0.61 percentage points [3] - Revenue from traditional Chinese and Western medicine reached 8.878 billion yuan, with a gross margin of 34.85%, while non-pharmaceutical products generated 1.353 billion yuan with a gross margin of 51.10% [3] Store Expansion and Market Strategy - The company has expanded its store network significantly, with 1,135 new direct stores and 440 new franchise stores added in H1 2024 [3] - The company is focusing on consolidating its presence in the Central South, East China, and North China regions, with notable new store openings in these areas [3] - The O2O strategy is being enhanced through the integration of membership, big data, and online healthcare services, with over 10,000 stores now part of the O2O multi-channel platform [3]

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2024-083 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于使用闲置募集资金委托理财到期赎回 并继续委托理财的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 本次赎回产品名称：招商银行点金系列看涨两层区间 29 天结构性存款 （2000 万）、利多多公司稳利 24JG3401 期(月月滚利 5 期)人民币对公结构性存 款（7700 万） 赎回金额：9,700.00 万元 | | | 二、 本次委托理财的情况 1、委托理财目的 在确保不变相改变募集资金用途与不影响募集资金投资项目正常运行的情 况下，提高闲置募集资金的使用效率，增加公司收益，降低财务成本。 本次继续委托理财金额：8,100.00 万元 已履行的审议程序：经公司第四届董事会第三十八次会议审议通过 特别风险提示：公司将对投资产品进行严格评估，尽管公司选择本金保障 类理财产品，但金融市 ...

证券研究报告 非金融公司|公司点评|益丰药房（603939） 业绩增长稳健，彰显经营韧性 请务必阅读报告末页的重要声明 glzqdatemark1 2024年09月03日 证券研究报告 |报告要点 公司发布 2024 年半年报，2024 年上半年实现收入 117.62 亿元，同比增长 9.86%；归母净利 润 7.98 亿元，同比增长 13.13%；扣非后归母净利润 7.86 亿元，同比增长 15.77%。公司坚持 "区域聚焦，稳健扩张"的发展战略，通过"新开+并购+加盟"的拓展模式，深耕中南、华东、华 北市场，截至 2024 年 6 月底，公司门店总数达 14,736 家（含加盟店 3,426 家），较 2023 年 底增加 1,486 家。 |分析师及联系人 郑薇 SAC：S0590521070002 请务必阅读报告末页的重要声明 1 / 5 非金融公司|公司点评 glzqdatemark2 2024年09月03日 益丰药房(603939) 业绩增长稳健，彰显经营韧性 | --- | --- | |----------------------------|-------------------| | | ...

Investment Rating - The report assigns a "Buy" rating for Yifeng Pharmacy (603939.SH) [1] Core Views - Yifeng Pharmacy achieved a revenue of 11.762 billion yuan in H1 2024, representing a year-on-year growth of 9.86%, and a net profit attributable to shareholders of 798 million yuan, up 13.13% from the previous year [1] - The company is focusing on balanced development and prioritizing efficiency amid industry competition [1] - The retail business gross margin for H1 2024 was 40.94%, slightly up by 0.06 percentage points compared to the same period in 2023 [1] - The company is expected to see revenue growth from 24.786 billion yuan in 2024 to 29.171 billion yuan in 2026, with net profits projected to rise from 1.614 billion yuan to 2.121 billion yuan in the same period [3][4] Summary by Sections Company Overview - Yifeng Pharmacy has maintained a net increase in store numbers despite industry challenges, with 1,575 new stores opened in H1 2024, including 842 self-built stores and 293 acquired stores [1] - The company is adapting to industry changes by enhancing management efficiency and adjusting store opening and closing strategies [1] Financial Performance - The company reported a gross margin of 40.94% in H1 2024, with drug gross margins at 36.46% (down 0.12 percentage points) and non-drug gross margins at 51.1% (up 0.03 percentage points) [1] - Forecasts indicate that the company's revenue will grow from 24.786 billion yuan in 2024 to 29.171 billion yuan in 2026, with corresponding net profits of 1.614 billion yuan and 2.121 billion yuan [3][4] Market Position - Yifeng Pharmacy is positioned as a leading player in the retail pharmacy sector, benefiting from the increasing concentration in the industry due to policy support [2] - The company operates the largest number of chain pharmacies among private pharmacy chains in China, with 14,736 stores as of June 2024 [1]

Financial Performance - Revenue for the first half of 2024 reached 11.762 billion yuan, a year-on-year increase of 9.86% [3] - Net profit attributable to the parent company was 798 million yuan, up 13.13% year-on-year [3] - Non-GAAP net profit was 786 million yuan, representing a 15.77% increase [3] - Proposed cash dividend of 0.25 yuan per share, totaling 303 million yuan [4] Store Operations - Total stores reached 14,736 by the end of the reporting period, including 3,426 franchise stores [3] - Added 1,575 new stores in H1 2024: 842 self-built, 293 acquired, and 440 franchise stores [3] - Relocated 17 stores and closed 72 stores during the reporting period [3] New Retail Business - Membership base reached 96.16 million, with member sales accounting for 77% of total sales [3] - O2O business covered over 10,000 directly operated stores across major cities [3] - Internet sales reached 1.096 billion yuan, a 20.18% year-on-year increase [3] - O2O sales: 878 million yuan, up 26.33% [3] - B2C sales: 218 million yuan, up 0.46% [3] Industry Trends and Strategy - Pharmacy remains a crucial community health gateway, especially for elderly customers [4] - Online platforms complement rather than replace physical stores due to the need for face-to-face services [4] - Global pharmacy trends show diversification into cosmetics, functional foods, and daily necessities [5] - China's 1-2 person households (50% of total) increasingly rely on pharmacies for health services [6][7] Challenges and Responses - Q2 growth slowdown attributed to reduced health product consumption and inventory adjustments [8] - Intensified competition expected to ease as some stores close in July [8] - M&A activity slowed due to market uncertainty, with significant deals expected to resume next year [9] Future Focus Areas - Store optimization through "people-goods-field" transformation [10] - Enhanced professional service models to improve customer engagement [10] - Expansion of health product procurement and sales systems [10] - Comprehensive cost reduction and digital system construction [10] - Organizational innovation and talent system development [10]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 20% relative to the benchmark index within the next six months [8]. Core Views - The company has demonstrated steady revenue and profit growth, with H1 2024 revenue reaching 11.762 billion yuan, a 9.86% increase year-on-year, and net profit attributable to shareholders at 798 million yuan, up 13.13% [5][6]. - The retail segment showed robust growth with revenue of 10.398 billion yuan (+8.32%), while the wholesale segment experienced rapid expansion with revenue of 999 million yuan (+20.91%) [6]. - The company continues to adhere to a regional focus strategy, expanding its store count to 14,736 by mid-2024, with a net increase of 1,486 stores compared to the end of 2023 [7]. Financial Performance - For H1 2024, the company reported a gross margin of 40.05% and a net margin of 7.31%, with a slight decrease in net margin by 0.15 percentage points [6]. - The company’s operating cash flow for H1 2024 was 1.822 billion yuan, reflecting a significant increase of 29.41% [5]. - The projected revenue for 2024-2026 is expected to be 24.921 billion yuan, 28.816 billion yuan, and 33.342 billion yuan respectively, with net profits projected at 1.599 billion yuan, 1.923 billion yuan, and 2.318 billion yuan [8][9]. Valuation Metrics - The current price-to-earnings (P/E) ratio is 14.41, with future P/E ratios projected at 15.29 for 2024, 12.71 for 2025, and 10.55 for 2026 [9]. - The price-to-book (P/B) ratio is currently at 2.49, expected to decrease to 2.11 by 2024 and further to 1.55 by 2026 [9].